Current Report Filing (8-k)
June 11 2020 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June
10, 2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
|
|
¨
|
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
|
|
¨
|
Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per
share
|
|
ZYNE
|
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07 Submission of Matters to Vote of Security Holders
On June 10, 2020, Zynerba Pharmaceuticals,
Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”).
The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders
at the Annual Meeting.
(a) Proposal 1 — Election of Seven
Directors. Each director nominee was elected to the Board of Directors to serve as a director until the 2021 Annual Meeting
of the Stockholders or until his or her respective successor is elected and qualified, as follows:
Name
|
|
For
|
|
Withheld
|
|
Broker Non-
Votes
|
|
Armando Anido
|
|
|
4,368,941
|
|
|
339, 031
|
|
|
10,764,389
|
|
John P. Butler
|
|
|
3,911,474
|
|
|
796,498
|
|
|
10,764,389
|
|
Warren D. Cooper, MB, BS, BSc, MFPM
|
|
|
3,917,633
|
|
|
790,399
|
|
|
10,764,389
|
|
William J. Federici
|
|
|
4,425,386
|
|
|
282,586
|
|
|
10,764,389
|
|
Daniel L. Kisner, MD
|
|
|
4,441,473
|
|
|
266,499
|
|
|
10,764,389
|
|
Kenneth I. Moch
|
|
|
4,415,069
|
|
|
292,903
|
|
|
10,764,389
|
|
Pamela Stephenson
|
|
|
3,886,425
|
|
|
821,547
|
|
|
10,764,389
|
|
(b) Proposal 2 — Ratification of
Independent Registered Public Accountants. The appointment of KPMG LLP as the Company’s independent registered public
accounting firm for the 2020 fiscal year was ratified, as follows:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
|
14,941,522
|
|
|
303,519
|
|
|
227,320
|
|
|
-0-
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 11, 2020
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
By:
|
/s/ Suzanne Hanlon
|
|
|
Name: Suzanne Hanlon
|
|
|
Title: Secretary, Vice President and General Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2024 to May 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From May 2023 to May 2024